89bio Quarterly Balance Sheets Chart
Quarterly
|
Annual
89bio Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | ||||||||||||||||||||||||
| current assets: | ||||||||||||||||||||||||
| cash and cash equivalents | 129,076,000 | 315,396,000 | 126,060,000 | 91,411,000 | 212,218,000 | 217,573,000 | 316,161,000 | 251,926,000 | 245,441,000 | 350,930,000 | 55,255,000 | 72,401,000 | 60,618,000 | 54,889,000 | 52,432,000 | 39,695,000 | 35,714,000 | 68,007,000 | 98,183,000 | 141,551,000 | 68,199,000 | 85,532,000 | 93,335,000 | 16,188,000 |
| marketable securities | 432,088,000 | 323,384,000 | 313,895,000 | 332,363,000 | 319,166,000 | 344,715,000 | 262,709,000 | |||||||||||||||||
| prepaid and other current assets | 40,356,000 | 44,164,000 | 36,495,000 | 32,432,000 | 48,470,000 | 12,494,000 | 14,664,000 | 11,222,000 | 13,879,000 | 12,747,000 | 7,920,000 | 6,513,000 | 7,218,000 | 9,298,000 | 11,237,000 | 9,678,000 | 9,585,000 | 8,286,000 | 5,548,000 | 3,360,000 | 1,371,000 | 1,857,000 | 1,966,000 | 362,000 |
| total current assets | 601,520,000 | 682,944,000 | 476,450,000 | 456,206,000 | 579,854,000 | 574,782,000 | 593,534,000 | 459,526,000 | 491,874,000 | 493,630,000 | 196,080,000 | 199,854,000 | 146,568,000 | 135,409,000 | 161,982,000 | 167,036,000 | 180,573,000 | 197,936,000 | 210,202,000 | 222,538,000 | 75,291,000 | 87,413,000 | 95,326,000 | 16,588,000 |
| property and equipment | 77,000 | 85,000 | 23,000 | 17,000 | 27,000 | 37,000 | 46,000 | 58,000 | 68,000 | 78,000 | 92,000 | 105,000 | 121,000 | 138,000 | 150,000 | 146,000 | 154,000 | 161,000 | 166,000 | 177,000 | 191,000 | 204,000 | 155,000 | 49,000 |
| operating lease right-of-use assets | 1,256,000 | 1,409,000 | 1,572,000 | 1,760,000 | 1,942,000 | 2,118,000 | 2,293,000 | |||||||||||||||||
| other assets | 632,000 | 593,000 | 640,000 | 314,000 | 315,000 | 385,000 | 396,000 | 289,000 | 289,000 | 289,000 | 289,000 | 218,000 | 797,000 | 218,000 | 290,000 | 874,000 | 984,000 | 557,000 | 706,000 | 713,000 | 1,080,000 | 72,000 | 72,000 | |
| total assets | 603,485,000 | 685,031,000 | 478,685,000 | 458,297,000 | 582,138,000 | 577,322,000 | 596,269,000 | 460,111,000 | 492,511,000 | 494,319,000 | 196,824,000 | 200,580,000 | 147,595,000 | 135,765,000 | 162,422,000 | 168,056,000 | 181,711,000 | 198,654,000 | 211,074,000 | 223,428,000 | 76,562,000 | 87,689,000 | 95,553,000 | 18,354,000 |
| liabilities and stockholders’ equity | ||||||||||||||||||||||||
| current liabilities: | ||||||||||||||||||||||||
| accounts payable | 14,657,000 | 14,790,000 | 15,382,000 | 19,490,000 | 17,461,000 | 15,352,000 | 8,585,000 | 10,903,000 | 10,715,000 | 16,727,000 | 12,502,000 | 14,151,000 | 4,907,000 | 4,421,000 | 6,843,000 | 12,526,000 | 1,915,000 | 4,521,000 | 2,065,000 | 4,086,000 | 3,070,000 | 4,055,000 | 989,000 | 3,571,000 |
| accrued expenses | 24,170,000 | 22,343,000 | 20,020,000 | 18,898,000 | 18,663,000 | 20,295,000 | 20,530,000 | 14,133,000 | 15,056,000 | 7,117,000 | 11,944,000 | 13,437,000 | 14,388,000 | 8,979,000 | 10,194,000 | 7,319,000 | 5,665,000 | 3,938,000 | 6,048,000 | 5,338,000 | 3,721,000 | 3,732,000 | 4,620,000 | 2,992,000 |
| operating lease liabilities, current | 784,000 | 751,000 | 727,000 | 743,000 | 759,000 | 702,000 | 496,000 | |||||||||||||||||
| total current liabilities | 39,611,000 | 37,884,000 | 36,129,000 | 39,131,000 | 41,653,000 | 38,241,000 | 29,611,000 | 25,212,000 | 25,944,000 | 24,015,000 | 24,614,000 | 34,423,000 | 26,899,000 | 18,400,000 | 19,537,000 | 19,845,000 | 7,580,000 | 8,459,000 | 8,113,000 | 9,424,000 | 6,791,000 | 7,787,000 | 5,609,000 | 22,579,000 |
| operating lease liabilities, noncurrent | 679,000 | 888,000 | 1,090,000 | 1,281,000 | 1,463,000 | 1,640,000 | ||||||||||||||||||
| warrant liability | 295,000 | 516,000 | 487,000 | |||||||||||||||||||||
| term loan, noncurrent | 36,156,000 | 35,940,000 | 35,732,000 | 35,544,000 | 20,355,000 | 23,065,000 | ||||||||||||||||||
| other noncurrent liabilities | 5,306,000 | 4,566,000 | 4,429,000 | 3,752,000 | 3,750,000 | 3,837,000 | ||||||||||||||||||
| total liabilities | 81,752,000 | 79,573,000 | 77,896,000 | 80,195,000 | 67,221,000 | 66,783,000 | 59,963,000 | 49,902,000 | 50,525,000 | 48,489,000 | 44,992,000 | 48,005,000 | 67,410,000 | 33,024,000 | 36,465,000 | 21,286,000 | 9,006,000 | |||||||
| commitments and contingencies | ||||||||||||||||||||||||
| stockholders’ equity: | ||||||||||||||||||||||||
| common stock | 148,000 | 146,000 | 120,000 | 106,000 | 105,000 | 95,000 | 93,000 | 75,000 | 75,000 | 73,000 | 51,000 | 44,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 20,000 | 14,000 | 14,000 | 14,000 | 1,000 |
| additional paid-in capital | 1,528,753,000 | 1,500,713,000 | 1,224,617,000 | 1,082,884,000 | 1,072,579,000 | 1,020,076,000 | 993,455,000 | 827,878,000 | 824,977,000 | 790,076,000 | 467,374,000 | 443,612,000 | 344,319,000 | 341,759,000 | 339,218,000 | 333,673,000 | 331,281,000 | 328,055,000 | 326,046,000 | 324,501,000 | 165,668,000 | 164,028,000 | 163,526,000 | 341,000 |
| accumulated other comprehensive income | 122,000 | 385,000 | 563,000 | 1,269,000 | -683,000 | -519,000 | 190,000 | 6,000 | 4,000 | |||||||||||||||
| accumulated deficit | -1,007,290,000 | -895,786,000 | -824,511,000 | -706,157,000 | -557,084,000 | -509,113,000 | -457,432,000 | -417,197,000 | -382,472,000 | -344,079,000 | -315,243,000 | -290,641,000 | -263,836,000 | -238,782,000 | -213,217,000 | -186,929,000 | -158,600,000 | -137,877,000 | -123,095,000 | -110,514,000 | -95,911,000 | -84,140,000 | -73,596,000 | -54,313,000 |
| total stockholders’ equity | 521,733,000 | 605,458,000 | 400,789,000 | 378,102,000 | 514,917,000 | 510,539,000 | 536,306,000 | 410,209,000 | 441,986,000 | 445,830,000 | 151,832,000 | 152,575,000 | 80,185,000 | 102,741,000 | 125,957,000 | 146,770,000 | 172,705,000 | 190,195,000 | 202,961,000 | 214,004,000 | 69,771,000 | 79,902,000 | 89,944,000 | |
| total liabilities and stockholders’ equity | 603,485,000 | 685,031,000 | 478,685,000 | 458,297,000 | 582,138,000 | 577,322,000 | 596,269,000 | 460,111,000 | 492,511,000 | 494,319,000 | 196,824,000 | 200,580,000 | 147,595,000 | 135,765,000 | 162,422,000 | 168,056,000 | 181,711,000 | 198,654,000 | 211,074,000 | 223,428,000 | 76,562,000 | 87,689,000 | ||
| preferred stock, 0.001 par value: 10,000,000 shares authorized; none issued and outstanding | ||||||||||||||||||||||||
| term loan, current | 4,770,000 | 1,892,000 | 6,667,000 | 7,500,000 | 5,000,000 | 2,500,000 | ||||||||||||||||||
| operating lease liabilities, non-current | 1,817,000 | |||||||||||||||||||||||
| term loan, non-current | 24,795,000 | 24,637,000 | 24,483,000 | 24,332,000 | 19,691,000 | 12,958,000 | 12,050,000 | 14,473,000 | 16,898,000 | 1,441,000 | 1,426,000 | |||||||||||||
| other non-current liabilities | 3,740,000 | |||||||||||||||||||||||
| preferred stock, 0.001 par value; 10,000,000 shares authorized, none issued and outstanding | ||||||||||||||||||||||||
| short-term available-for-sale securities | 196,378,000 | 232,554,000 | 129,953,000 | 132,905,000 | 120,940,000 | 78,707,000 | 71,197,000 | 98,288,000 | 117,638,000 | 135,249,000 | 121,618,000 | |||||||||||||
| operating lease right-of-use asset | 238,000 | 280,000 | 322,000 | 363,000 | 403,000 | 109,000 | ||||||||||||||||||
| operating lease liability, current | 176,000 | 173,000 | 171,000 | 168,000 | 168,000 | 104,000 | ||||||||||||||||||
| operating lease liability, non-current | 53,000 | 98,000 | 142,000 | 186,000 | 229,000 | |||||||||||||||||||
| accumulated other comprehensive loss | -547,000 | -594,000 | -240,000 | -350,000 | -440,000 | -318,000 | -256,000 | -64,000 | -3,000 | -10,000 | -3,000 | |||||||||||||
| restricted cash | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 25,000 | 24,000 | 24,000 | 25,000 | 38,000 | ||||||||||||
| other non-current liability | 501,000 | 395,000 | 275,000 | 151,000 | 30,000 | |||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized as of december 31, 2022 and 2021; no shares issued and outstanding as of december 31, 2022 and 2021 | ||||||||||||||||||||||||
| liability related to public offering | 28,186,000 | |||||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized as of december 31, 2021 and 2020, respectively, no shares issued and outstanding as of december 31, 2021 and 2020, respectively | ||||||||||||||||||||||||
| short-term investments | 106,446,000 | 77,602,000 | 5,697,000 | |||||||||||||||||||||
| preferred stock, 0.001 par value, 10,000,000 shares authorized as of december 31, 2020 and 2019, respectively, no shares issued and outstanding as of december 31, 2020 and 2019, respectively | ||||||||||||||||||||||||
| deferred tax assets | 89,000 | |||||||||||||||||||||||
| liabilities, convertible preferred stock and stockholders’ equity | ||||||||||||||||||||||||
| convertible preferred stock liability | 16,016,000 | |||||||||||||||||||||||
| convertible preferred stock, 0.001 par value; 0 shares and 60,000,000 shares authorized as of december 31, 2019 and 2018, respectively; 0 shares and 24,000,000 shares issued and outstanding as of december 31, 2019 and 2018, respectively; liquidation value of 0 and 24,000 as of december 31, 2019 and 2018, respectively | ||||||||||||||||||||||||
| stockholders’ equity | ||||||||||||||||||||||||
| total liabilities, convertible preferred stock and stockholders’ equity | 95,553,000 | |||||||||||||||||||||||
| deferred offering costs | 1,628,000 | |||||||||||||||||||||||
| liabilities, convertible preferred stock, convertible preferred shares and stockholders’ deficit | ||||||||||||||||||||||||
| convertible preferred stock | 49,746,000 | |||||||||||||||||||||||
| convertible preferred shares | ||||||||||||||||||||||||
| stockholders’ deficit: | ||||||||||||||||||||||||
| ordinary shares | ||||||||||||||||||||||||
| total stockholders’ deficit | -53,971,000 | |||||||||||||||||||||||
| total liabilities, convertible preferred stock, convertible preferred shares and stockholders’ deficit | 18,354,000 | |||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||
| research and development | 6,680,000 | |||||||||||||||||||||||
| general and administrative | 1,518,000 | |||||||||||||||||||||||
| total operating expenses | 8,198,000 | |||||||||||||||||||||||
| income from operations | 8,198,000 | |||||||||||||||||||||||
| other incomes | 10,470,000 | |||||||||||||||||||||||
| net income before tax | 18,668,000 | |||||||||||||||||||||||
| income tax expense | 57,000 | |||||||||||||||||||||||
| net income and comprehensive loss | 18,725,000 | |||||||||||||||||||||||
| net income per share | -30,630 | |||||||||||||||||||||||
| weighted-average shares used for eps calculation | 611,226,000 |
We provide you with 20 years of balance sheets for 89bio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of 89bio. Explore the full financial landscape of 89bio stock with our expertly curated balance sheets.
The information provided in this report about 89bio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.